Holen Sie sich die Stockscreener-App
16.32
4.48%
0.70
Schlusskurs vom Vortag:
$15.62
Offen:
$15.69
24-Stunden-Volumen:
222.56K
Relative Volume:
1.29
Marktkapitalisierung:
$682.73M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+23.82%
1M Leistung:
+62.87%
6M Leistung:
+111.13%
1J Leistung:
+0.00%
1-Tages-Spanne:
$15.44
$16.67
1-Wochen-Bereich:
$13.07
$16.67
52-Wochen-Spanne:
$5.83
$26.25
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Firmenname
Zenas Biopharma Inc
Sektor
Branche
Telefon
857-271-2954
Adresse
852 WINTER STREET, SUITE 250, WALTHAM
Vergleichen Sie ZBIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
16.32 | 598.65M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-20 | Eingeleitet | Wedbush | Outperform |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-05 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-10-08 | Eingeleitet | Citigroup | Buy |
| 2024-10-08 | Eingeleitet | Guggenheim | Buy |
| 2024-10-08 | Eingeleitet | Jefferies | Buy |
| 2024-10-08 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Zenas Biopharma Inc Aktie (ZBIO) Neueste Nachrichten
What analysts say about Zenas BioPharma Inc. stockRecord-setting profit potential - jammulinksnews.com
Zenas BioPharma Inc. Stock Analysis and ForecastOutstanding trading profits - jammulinksnews.com
Is Zenas BioPharma Inc. a good long term investmentFree Consultation - jammulinksnews.com
What drives Zenas BioPharma Inc. stock priceStrong return on assets - jammulinksnews.com
IgG4-Related Disease Market Outlook Driven by Advancing - openPR.com
What makes Zenas BioPharma Inc. stock price move sharplyFree Stock Market Group - beatles.ru
Why Zenas BioPharma Inc. stock attracts strong analyst attentionHigh Return Investment Tips - Newser
How Zenas BioPharma Inc. stock performs during market volatilityFree Stock Tips Group - Newser
Zenas BioPharma Insiders Added US$2.11m Of Stock To Their Holdings - 富途牛牛
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zenas BioPharma, Inc. (ZBIO) And Encourages Stockholders to Reach Out - ACCESS Newswire
Citi reiterates Buy rating on Zenas Biopharma stock with $27 price target - Investing.com Canada
ZBIO Crosses Above Key Moving Average Level - Nasdaq
Promising Future for Zenas BioPharma: Buy Rating Backed by Unique Product Advantage and Strong Pipeline Developments - TipRanks
Morgan Stanley assumes coverage on Zenas Biopharma stock with Overweight rating - Investing.com Canada
Innovative Approach and Upcoming Catalysts Drive Buy Rating for Zenas BioPharma - TipRanks
Zenas BioPharma, Inc.(NasdaqGS: ZBIO) dropped from Russell 2000 Growth Index - MarketScreener
Rhumbline Advisers Sells 27,428 Shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO) - Defense World
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming DeadlinesZBIO - Finansavisen
ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas - GlobeNewswire
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma - Business Wire
Securities Fraud Class Action Filed Against Zenas BioPharma, Inc. (ZBIO)Levi & Korsinsky Reminds Investors of June 16, 2025 - ACCESS Newswire
ZBIO Investors Have Final Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm - marketscreener.com
FINAL ALERT NOTICEZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities LawsuitContact the DJS Law Group to Discuss Your RightsZBIO - marketscreener.com
June 16, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ZBIO - PR Newswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma - The Malaysian Reserve
Join Class Action to Recover Losses from Zenas BioPharma, Inc. (ZBIO)Contact Levi & Korsinsky Before June 16, 2025 - ACCESS Newswire
Investor Alert: Deadline Approaching to Join Zenas BioPharma, Inc. (ZBIO) Class ActionContact Levi & Korsinsky - ACCESS Newswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma - StreetInsider
Zenas BioPharma, Inc. Sued for Securities Law Violations – - GlobeNewswire
ZBIO Deadline: ZBIO Investors with Losses in Excess of $100K Have Opportunity to Lead Zenas BioPharma, Inc. Securities Lawsuit Filed by The Rosen Law Firm - GuruFocus
Zenas BioPharma, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & ... - Bluefield Daily Telegraph
ZBIO IMPORTANT DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW - GlobeNewswire
ZBIO Investors Have the Opportunity to Lead the Zenas BioPharma Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - StreetInsider
Finanzdaten der Zenas Biopharma Inc-Aktie (ZBIO)
Es liegen keine Finanzdaten für Zenas Biopharma Inc (ZBIO) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Zenas Biopharma Inc-Aktie (ZBIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Xiao Ting | Director |
Feb 07 '25 |
Buy |
7.76 |
10,000 |
77,600 |
47,000 |
| MOULDER LEON O JR | Chief Executive Officer |
Dec 04 '24 |
Buy |
9.98 |
45,000 |
449,100 |
241,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Dec 03 '24 |
Buy |
10.76 |
25,000 |
269,000 |
196,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Nov 18 '24 |
Buy |
15.00 |
7,500 |
112,500 |
168,655 |
| MOULDER LEON O JR | Chief Executive Officer |
Nov 19 '24 |
Buy |
14.57 |
2,500 |
36,425 |
171,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 18 '24 |
Buy |
17.91 |
10,000 |
179,100 |
1,662,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 20 '24 |
Buy |
18.45 |
5,000 |
92,270 |
1,672,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 19 '24 |
Buy |
17.89 |
5,000 |
89,450 |
1,667,039 |
| Enavate Sciences GP, LLC | 10% Owner |
Sep 16 '24 |
Buy |
17.00 |
882,353 |
15,000,001 |
3,761,359 |
| Lu Hongbo | Director |
Sep 13 '24 |
Buy |
17.00 |
58,823 |
999,991 |
58,823 |
3.32%
1.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):